Estabrook Capital Management Sells 137 Shares of Humana Inc. (NYSE:HUM)

Estabrook Capital Management reduced its stake in Humana Inc. (NYSE:HUM) by 23.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 458 shares of the insurance provider’s stock after selling 137 shares during the period. Estabrook Capital Management’s holdings in Humana were worth $116,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Humana in the fourth quarter worth $26,720,000. APG Asset Management N.V. lifted its holdings in shares of Humana by 230.0% in the 4th quarter. APG Asset Management N.V. now owns 86,229 shares of the insurance provider’s stock valued at $21,127,000 after acquiring an additional 60,098 shares during the last quarter. Greenland Capital Management LP bought a new stake in Humana during the fourth quarter worth approximately $200,000. Bank of Nova Scotia boosted its holdings in shares of Humana by 99.7% in the 4th quarter. Bank of Nova Scotia now owns 107,747 shares of the insurance provider’s stock worth $27,336,000 after purchasing an additional 53,802 shares during the period. Finally, Shelton Capital Management raised its holdings in Humana by 148.2% during the 4th quarter. Shelton Capital Management now owns 11,892 shares of the insurance provider’s stock valued at $3,017,000 after buying an additional 7,100 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

NYSE:HUM opened at $280.63 on Wednesday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The stock’s 50-day moving average price is $266.00 and its 200-day moving average price is $271.01. The stock has a market capitalization of $33.87 billion, a PE ratio of 28.20, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HUM. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Finally, StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a report on Monday. Seventeen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Humana currently has an average rating of “Hold” and a consensus price target of $280.17.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.